Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?

Page 1 of 2

Should Novo Nordisk A/S (ADR) (NYSE:NVO) investors track the following data?

In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to track Mr. Market. A couple of the most under-the-radar are hedge fund and insider trading movement. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the elite hedge fund managers can outperform their index-focused peers by a superb margin (see just how much).

Equally as crucial, bullish insider trading activity is a second way to look at the marketplace. Just as you’d expect, there are many motivations for an insider to sell shares of his or her company, but only one, very clear reason why they would behave bullishly. Various empirical studies have demonstrated the market-beating potential of this strategy if “monkeys” know where to look (learn more here).

Furthermore, let’s analyze the latest info about Novo Nordisk A/S (ADR) (NYSE:NVO).

Novo Nordisk A/S (ADR) (NYSE:NVO)

Hedge fund activity in Novo Nordisk A/S (ADR) (NYSE:NVO)

In preparation for the third quarter, a total of 17 of the hedge funds we track held long positions in this stock, a change of 31% from the first quarter. With the smart money’s sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their holdings considerably.

Out of the hedge funds we follow, Renaissance Technologies, managed by Jim Simons, holds the largest position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies has a $433.1 million position in the stock, comprising 1.1% of its 13F portfolio. The second largest stake is held by Fisher Asset Management, managed by Ken Fisher, which held a $417.1 million position; 1.1% of its 13F portfolio is allocated to the company. Remaining hedge funds that are bullish include Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital, Tom Gayner’s Markel Gayner Asset Management and William B. Gray’s Orbis Investment Management.

Now, certain bigger names were leading the bulls’ herd. Renaissance Technologies, managed by Jim Simons, established the biggest position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies had 433.1 million invested in the company at the end of the quarter. Ken Fisher’s Fisher Asset Management also made a $417.1 million investment in the stock during the quarter. The following funds were also among the new NVO investors: Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital, Tom Gayner’s Markel Gayner Asset Management, and William B. Gray’s Orbis Investment Management.

Insider trading activity in Novo Nordisk A/S (ADR) (NYSE:NVO)

Insider buying made by high-level executives is most useful when the company we’re looking at has seen transactions within the past half-year. Over the last half-year time period, Novo Nordisk A/S (ADR) (NYSE:NVO) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Novo Nordisk A/S (ADR) (NYSE:NVO). These stocks are Dr. Reddy’s Laboratories Limited (ADR) (NYSE:RDY), Pharmacyclics, Inc. (NASDAQ:PCYC), Forest Laboratories, Inc. (NYSE:FRX), Allergan, Inc. (NYSE:AGN), and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). This group of stocks belong to the drug manufacturers – other industry and their market caps are closest to NVO’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!